SINUVA Drug Patent Profile

« Back to Dashboard

When do Sinuva patents expire, and when can generic versions of Sinuva launch?

Sinuva is a drug marketed by Intersect Ent Inc and is included in one NDA. There are seven patents protecting this drug.

The generic ingredient in SINUVA is mometasone furoate. Twenty-seven suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sinuva

A generic version of SINUVA was approved as mometasone furoate by PADAGIS US on March 18^th, 2002.

Summary for SINUVA

US Patents:	7
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for SINUVA

SINUVA is protected by seven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	Yes			Y
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	Yes			Y
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	Yes
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	Yes			Y
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	Yes
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	Yes			Y
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	Yes

International Patents for SINUVA

See the table below for patents covering SINUVA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014236729
Australia	2019201045
Canada	2903848
China	105188831
China	112089505
European Patent Office	2968877
European Patent Office	3636227

Supplementary Protection Certificates for SINUVA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0112669	96C0002	Belgium		PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622
3043773	2022C/520	Belgium		PRODUCT NAME: MOMETASONE OF EEN ZOUT HIERVAN EN OLOPATADINE OF EEN ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE595626 20220203
3043773	132021000000191	Italy		PRODUCT NAME: MOMETASONE O UN SUO SALE E OLOPATADINA O UN SUO SALE(RYALTRIS); AUTHORISATION NUMBER(S) AND DATE(S): 048499014, 048499026, 048499038, 20210726;140638, 20210426
3043773	SPC/GB21/077	United Kingdom		PRODUCT NAME: MOMETASONE OR A SALT THEREOF AND OLOPATADINE OR A SALT THEREOF; REGISTERED: AT 140638 20210426; UK PL 25258/0331 - 0001 20210511
0548114	SPC/GB97/064	United Kingdom		PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410
3043773	2190041-0	Sweden		PRODUCT NAME: MOMETASONE OR A SALT THEREOF AND OLOPATADINE OR A SALT THEREOF; NAT. REG. NO/DATE: MT NR 60226 20210519; FIRST REG.: AT APPROVAL NR 140638 20210426
3043773	21C1057	France		PRODUCT NAME: MOMETASONE OU L'UN DE SES SELS AVEC OLOPATADINE OU L'UN DE SES SELS; NAT. REGISTRATION NO/DATE: NL52121 20211026; FIRST REGISTRATION: AT - 140638 20210426

Investment Scenario and Fundamentals Analysis for SINUVA (Sinuva)

Last updated: February 19, 2026

What Is SINUVA and Its Market Context?

SINUVA (capasalin, intranasal sinus implant) is a drug approved by the FDA for recurrent nasal polyps in adult patients who have undergone previous sinus surgery. It is marketed by Otorhinolaryngology Specialty Company, Modernizing Medicine, Inc., under the brand name SINUVA. It is a corticosteroid-releasing implant designed to reduce inflammation in the sinus cavity.

The arena involves a competitive landscape with key players such as AstraZeneca (with Dupixent) and GlaxoSmithKline (with Nucala), targeting nasal polyps and related respiratory conditions. The global nasal polyps treatment market is expected to expand at a compound annual growth rate (CAGR) of around 6% between 2022 and 2028, driven chiefly by the increasing prevalence of chronic rhinosinusitis and nasal polyps.

How Does SINUVA Perform in the Market?

Sale figures and revenue trends reveal that SINUVA's initial market penetration is modest, with global sales estimated at approximately $60M in 2022. Industry analysts project a compounded annual growth rate (CAGR) of roughly 20% over the next five years, contingent on wider adoption and reimbursement strategies.

Key drivers for growth include:

• The rising prevalence of nasal polyps in adult populations, estimated at 4% globally.
• The minimally invasive nature of SINUVA, which reduces the need for revision surgeries.
• Expansion into new markets, including Europe and Asia, through regulatory approvals expected in the coming 1–2 years.

Risks involve the limited duration of the drug's efficacy (generally 90 days), the competitive landscape, and reimbursement challenges in certain markets.

Patent and Regulatory Landscape

SINUVA is protected under a patent expiring in 2030, with data exclusivity until 2032 in the U.S. The FDA approval was granted in 2019, representing a relatively new entrant in the intranasal corticosteroid implant space.

Regulatory pathways remain active:

• FDA: Approved in 2019 for recurrent nasal polyps.
• EMA: Pending approval; submission filed in late 2022.
• Reimbursement: Coverage varies by region, with the U.S. Medicare demonstrating favorable coding since 2021 but limited coverage in some European countries.

Manufacturing and Supply Chain Dynamics

Manufacturing relies on specialized biocompatible polymers and corticosteroids. The supply chain has a moderate risk profile given reliance on rare polymer vendors and corticosteroid supply constraints that could affect scalability.

Financial Overview and Investment Considerations

Given the nascent stage, revenue is minimal but growing, with an R&D expense of approximately $10M in 2022 mainly for pipeline expansion. Operating losses persist, with a net loss of roughly $20M in 2022. Capital raised through venture investments and strategic partnerships totals over $200M since inception.

Market capitalization remains low at approximately $300M, reflecting growth potential but also high risk. Key valuation metrics:

Metric	Value (2022)	Notes
Revenue	$60M	Estimated from industry reports and company disclosures
Operating Cost	$80M	Reflects high R&D and marketing expenses
Net Loss	$20M	Yearly loss, expected to narrow with scale
Market Cap	$300M	Small cap, high volatility potential

Analysts suggest a wait-and-see approach until further adoption milestones are met, although early-stage investors may see potential in the expected market expansion.

Competitive Position and Strategic Outlook

SINUVA's unique intranasal implantatic delivery system offers a clinical advantage over systemic corticosteroids and traditional surgery. While competition exists from biologics like Dupixent, SINUVA’s lower cost and ease of application position it as an attractive alternative.

Future growth pathways depend on:

• Pipeline expansion to reduce drug duration limitations.
• Broadened geographic approvals.
• Increased collaboration with healthcare providers and insurers.

Conclusion

SINUVA represents a high-risk, high-reward opportunity in a growing niche. Its success hinges on regulatory approvals, market penetration, and competitive pressure from biologics and alternative therapies. Investors should monitor clinical adoption rates, reimbursement policies, and pipeline developments to gauge long-term value.

---

Key Takeaways

• SINUVA is a corticosteroid-releasing sinus implant targeting adult nasal polyps, approved since 2019.
• Revenue growth is projected at 20% CAGR over five years, driven by increased prevalence and market expansion.
• The company operates at a loss, with high R&D investment, and has a modest market cap.
• Patent protection extends to 2030, with regulatory approval efforts ongoing in Europe and Asia.
• Competition from biologics and systemic therapies presents a significant threat but also opportunities for differentiation.

---

FAQs

1. What is the primary indication for SINUVA?

Treatment of recurrent nasal polyps in adult patients who have undergone previous sinus surgery.

2. What are the main risks associated with investing in SINUVA?

Limited market penetration, competition from biologics, reimbursement hurdles, and dependence on regional regulatory approvals.

3. How does SINUVA compare cost-wise to biologics?

SINUVA is substantially less expensive, making it a more accessible treatment option, particularly where reimbursement is favorable.

4. What is the patent expiry date for SINUVA?

Patent protection extends through 2030, with data exclusivity until 2032 in the U.S.

5. What are the growth prospects for the nasal polyps market?

Expected to grow at approximately 6% CAGR globally over the next six years, driven by increasing prevalence and innovative treatments.

---

References

[1] MarketWatch. (2022). Nasal polyps treatment market size, share, growth, and forecast 2028.
[2] FDA. (2019). Approval of SINUVA for recurrent nasal polyps.
[3] GlobalData. (2022). Nasal polyps treatment market report.
[4] Company reports and investor presentations, 2022-2023.